Last updated on December 2019

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis


Brief description of study

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Clinical Study Identifier: NCT03222609

Find a site near you

Start Over

Ucsd /Id# 164084

La Jolla, CA United States
  Connect »

Usc /Id# 164095

Los Angeles, CA United States
  Connect »

Mayo Clinic /ID# 164201

Jacksonville, FL United States
  Connect »

University of Utah /ID# 164116

Salt Lake City, UT United States
  Connect »